Spyre Therapeutics, Inc. (SYRE) · Aug 25, 2026 · Other events

Spyre’s SPY072 hits RA endpoints but falls short of monotherapy bar

Below the bar — Statistically significant low-dose DAS28-CRP benefit, but effect magnitude missed Spyre’s internal advancement target

SPY072 produced statistically significant RA signals, but the effect was not strong enough for Spyre to prioritize monotherapy development.

The key benchmark was meaningful enough efficacy to advance RA monotherapy, and the filing says that bar was not cleared. The result was not a clean failure: low-dose SPY072 statistically improved the primary DAS28-CRP endpoint, while other dose-endpoint combinations showed nominal significance. But Spyre explicitly says the magnitude did not justify prioritizing the program in RA.

The efficacy signal is narrower than the headline suggests. Both doses are described as statistically significant on one or more endpoints, but the primary result came from low dose, the ACR20 signal from high dose was only nominally significant, and ACR50 significance was reported for low dose. The release provides no effect sizes, response rates, confidence intervals, or p-values, so the depth and clinical importance of the benefit cannot be independently judged from this filing. 〔0〕

MeasureSPY072Placebo
Adverse events27%36%
Infections and infestations14%15%
Serious TEAEs11
Deaths0 reported1

Safety was reassuring, but it does not offset the efficacy shortfall. Adverse-event rates were numerically lower with SPY072 than placebo, infections were nearly identical, and neither serious treatment-emergent event was considered drug-related.

The read-through shifts SPY072 away from RA monotherapy and toward combinations or other diseases. Spyre is preserving the broader TL1A strategy, including SPY072 in psoriatic arthritis and axial spondyloarthritis, plus an IL-17A/F combination in hidradenitis suppurativa. Those upcoming studies were already scheduled rather than created by this release; the next named catalyst is the September 2026 SKYLINE Part A readout. The RA result itself was a scheduled Q3 event, not a timing surprise.

What to watch next

SKYLINE Part A readout, September 2026

Original filing on SEC EDGAR

More Spyre Therapeutics, Inc. news

Spyre’s SPY072 hits RA endpoints but falls short of monotherapy bar | SYRE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.